BioMarin Pharmaceutical announced preliminary financial impacts regarding its acquisition of Alesta Therapeutics, which closed on August 31, 2026. The company anticipates that significant one-time charges related to acquired research and development will materially impact its third quarter results and necessitate an update to its full-year 2026 guidance.
Key Highlights
- Acquired in-process research and development (IPR&D) pre-tax charges are estimated at $283 million for the third quarter 2026.
- Projected unfavorable impact of $1.50 to both GAAP and Non-GAAP diluted EPS for the third quarter 2026.
- Full-year 2026 total pre-tax charges expected to reach $320 million, including ongoing operating and transaction costs.
- Anticipated $1.55 negative impact to full-year 2026 GAAP and Non-GAAP EPS, with updated guidance expected alongside final third quarter results.